How to Cite
Abstract
Introduction. Inflammatory myofibroblastic tumors (IMTs) are rare soft tissue neoplasms that occur predominantly in young adults. IMTs occur most commonly occur in the lungs, are localised and have a favourable prognosis. The pathogenesis of IMTs is based on translocation of the ALK gene in more than half of the cases.
Case description. This article presents two clinical observations of the use of the ALK inhibitor crizotinib in young patients with advanced extrapulmonary IMTs with ALK gene alterations. In both cases, the duration of response to therapy was more than 10 years. In the first observation, a patient with inoperable IMT achieved disease stabilisation while receiving targeted therapy. In the second case, a patient with multiple lung, bone and lymph node metastases achieved a partial response to crizotinib therapy at the first follow-up evaluation, which persisted thereafter. In both cases, the therapy was well tolerated and no new adverse events were observed.
Conclusion. The use of the ALK inhibitor crizotinib in the advanced form of IMTs with ALK translocation made it possible to achieve long-term responses to the therapy (more than 10 years).
References
Siegal G.P., Bloem J.L., Cates H.M. WHO Classification of Tumors 5th edition Soft Tissue and Bone Tumors. WHO Iarc. 2020.
López de Sa A., Pascual A., Garcia Santos J., et al. Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report. World J Surg Oncol. 2021; 19: 1-8.-DOI: https://doi.org/10.1186/s12957-021-02438-5.
Siemion K., Reszec-Gielazyn J., Kisluk J., et al. What do we know about inflammatory myofibroblastic tumors? – A systematic review. Adv Med Sci. 2022; 67: 129-138.-DOI: https://doi.org/10.1016/J.ADVMS.2022.02.002.
Comandini D., Catalano F., Grassi M., et al. Outstanding response in a patient with ROS1-rearranged inflammatory myofibroblastic tumor of soft tissues treated with crizotinib: case report. Front Oncol. 2021; 11: 1745.-DOI: https://doi.org/10.3389/FONC.2021.658327/BIBTEX.
Shah A., Pey E., Achonu J.U., et al. Inflammatory myofibroblastic tumor 12 years after treatment for synovial sarcoma: a case report. Orthop Res Rev. 2021; 13: 163-169.-DOI: https://doi.org/10.2147/ORR.S333124.
Zeng X., Huang H., Li J., et al. The clinical and radiological characteristics of inflammatory myofibroblastic tumor occurring at unusual sites. Biomed Res Int. 2018.-DOI: https://doi.org/10.1155/2018/5679634.
Trahair T., Gifford A.J., Fordham A., et al. Crizotinib and surgery for long-term disease control in children and adolescents with ALK-positive inflammatory myofibroblastic tumors. JCO Precis Oncol. 2019; 3: 1-11.-DOI: https://doi.org/10.1200/PO.18.00297.
Preobrazhenskaya E.V., Suleymanova A.M., Bizin I.V., et al. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours. Histopathology. 2023.-DOI: https://doi.org/10.1111/his.14912.
Preobrazhenskaya E.V., Iyevleva A.G., Suleymanova AM., et al. Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors. Pediatr Blood Cancer. 2020; 67(5): e28220.-DOI: https://doi.org/10.1002/pbc.28220.
Chang J.C., Zhang L., Drilon A.E., et al. Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements. J Thorac Oncol. 2019; 14: 825-834.-DOI: https://doi.org/10.1016/J.JTHO.2018.12.003/ATTACHMENT/7986B17E-EFD4-4249-A6B0-7C41311E0854/MMC2.DOCX.
Ng Z.Y., Khaing C.T., Aggarwal I. Inflammatory myofibroblastic tumor: an under recognized differential of uterine mesenchymal tumors. Int J Gynecol Cancer. 2022; 32: 212-213.-DOI: https://doi.org/10.1136/IJGC-2021-003247.
Zhang C., Wang Z., Zhuang R., et al. Efficacy and resistance of ALK inhibitors in two inflammatory myofibroblastic tumor patients with ALK fusions assessed by whole exome and RNA sequencing. Onco Targets Ther. 2020; 13: 10335-10342.-DOI: https://doi.org/10.2147/OTT.S270481.
Gambacorti-Passerini C., Orlov S., Zhang L., et al. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol. 2018; 93: 607-614.-DOI: https://doi.org/10.1002/AJH.25043.
FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor. FDA. 2022. URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor (11.08.2022).
Cantera J.E., Alfaro M.P., Rafart D.C., et al. Inflammatory myofibroblastic tumours: a pictorial review. Insights Imaging. 2015; 6: 85.-DOI: https://doi.org/10.1007/S13244-014-0370-0.
Telugu R.B., Prabhu A.J., Kalappurayil N.B., et al. Clinicopathological study of 18 cases of inflammatory myofibroblastic tumors with reference to alk-1 expression: 5-year experience in a tertiary care center. J Pathol Transl Med. 2017; 51: 255-263.-DOI: https://doi.org/10.4132/JPTM.2017.01.12.
Baldi G.G., Brahmi M., Lo Vullo S., et al. The activity of chemotherapy in inflammatory myofibroblastic tumors: a multicenter, european retrospective case series analysis. Oncologist. 2020; 25: e1777-e1784.-DOI: https://doi.org/10.1634/theoncologist.2020-0352.
Schöffski P., Kubickova M., Wozniak A., et al. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. Eur J Cancer. 2021; 156: 12-23.-DOI: https://doi.org/10.1016/j.ejca.2021.07.016.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024